Minghui’s MHB088C will soon start phase 3 in China.
ApexOnco Front Page
Recent articles
After earlier masked probody setbacks, CytomX surprises with CX-2051.
Final survival analysis draws a blank, and Lantheus throws in the towel.
Conference activity picks up, with the big one – ASCO – at the end of the month.
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
Three off-the-shelf mRNA therapies join intismeran autogene.
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
